Comparative Pharmacology
Head-to-head clinical analysis: DYANAVEL XR 5 versus FOCALIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYANAVEL XR 5 versus FOCALIN.
DYANAVEL XR 5 vs FOCALIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CNS stimulant; blocks reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their synaptic concentrations.
Dexmethylphenidate is a central nervous system stimulant that blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their synaptic concentrations. The d-threo enantiomer of methylphenidate is responsible for the therapeutic activity.
20 mg orally once daily in the morning; may increase by 10 mg weekly based on response; maximum 60 mg/day.
Initial 2.5-5 mg orally twice daily, increase by 2.5-10 mg/day weekly; max 20 mg twice daily.
None Documented
None Documented
Terminal elimination half-life for d-amphetamine is 10-13 hours; for l-amphetamine, 13-16 hours. Clinical context: Twice-daily dosing may be required for sustained effect.
2-3 hours in children and adults; 4-5 hours in adolescents (due to slower metabolism). Clinical context: t1/2 supports twice-daily dosing (immediate-release) for continuous therapeutic effect
Renal: ~90% as unchanged amphetamine and metabolites. Fecal: minimal (<5%).
Renal: 80% (approximately 50% as unchanged drug, 30% as metabolites); Fecal: negligible
Category C
Category C
CNS Stimulant
CNS Stimulant